"No matter how you cut it, it is a very tough act to follow."
agreed but also glad MMM does not appear to be intimidated given his comments today. EXEL may not have to wait for full-blown OS to mature in CM9ER for comparison to KN426. PFS was only 31% reduced but ORR was also impressive at ~60%. These will probably be the first stats we hear from CM9ER. We're not talking about cures here and there's room for improvement. There's only 11.6% difference in patient survival at 12.8 months - minuscule HR indicates the result is real but still, it's not like a 50% difference in survival.... plenty of room for improvement.
I have to think the immunomodulatory activity of cabo will synergize with nivo more than axitinib does with Pembrolizumab.